ArticleFrontiers in molecular biosciences2026
Establishment of a rapid and highly sensitive direct-RAA-RDB detection platform: application in non-deletion α-thalassemia.
Article in Frontiers in molecular biosciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Recombinase-Aided Amplification (RAA) is widely applied in genetic diagnostics owing to its simplicity and speed, making it a primary choice for Point-of-Care Testing (POCT). However, standard protocols require nucleic acid extraction. By incorporating Reverse Dot Blot (RDB) technology, multiple loci can be detected in a single tube. Methods: Our team developed Direct-RAA-RDB, a specific and sensitive gene detection platform that eliminates the need for nucleic acid extraction. The applicability of the platform was evaluated for the detection of non-deletion α-thalassemia, focusing on three genotypes: HBA2: c.369C>G (α Results: The results showed that the Direct- RAA-RDB assay possesses strong specificity and high sensitivity while remaining simple to operate. The entire process is completed within 143 min, allowing for the rapid detection of non-deletion α-thalassemia in clinical settings. Because the platform does not require extraction reagents, extractors, or thermal cyclers, it can be performed in a constant-temperature water bath shaker. Discussion: This method significantly reduces equipment and reagent costs and offers broad potential for diverse genetic detection applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.